Biology:DPP9

From HandWiki
Short description: Protein-coding gene in the species Homo sapiens


A representation of the 3D structure of the protein myoglobin showing turquoise α-helices.
Generic protein structure example

Dipeptidyl peptidase 9 is an enzyme that in humans is encoded by the DPP9 gene.[1]

This gene encodes a protein that is a member of the S9B family in clan SC of the serine proteases. The protein has been shown to have post-proline dipeptidyl aminopeptidase activity, cleaving Xaa-Pro dipeptides from the N-termini of proteins. Although the activity of this protein is similar to that of dipeptidyl peptidase 4 (DPP4), it does not appear to be membrane bound.

In general, dipeptidyl peptidases appear to be involved in the regulation of the activity of their substrates and have been linked to a variety of diseases including type 2 diabetes, obesity and cancer. Several transcript variants of this gene have been described but not fully characterized.[1] More specifically, DPP9 interacts with the NLRP1 protein and affects the level of activation of the NLPR1 inflammasome. This function involves binding to a complex of full length NLRP1 and a proinflammatory fragment of NLRP1 after activation by autocleavage.[2][3] A similiar mechanism allows DPP9 to regulate the CARD8 inflammasome. [4]

This gene has also been linked to severe COVID-19.

Medical Genetics

Mutations in NLRP1 that block DPP9 interaction lead to a rare Mendelian condition called Autoinflammation with Arthritis and Dyskeratosis[5][6] A homozygous recessive syndrome dubbed Hatipoğlu syndrome is attributed to mutations in DPP9 with phenotype of failure to thrive, skin manifestations, pancytopenia, and susceptibility to infections.[7] Genetic analysis of knockout alleles of DPP9 in mice and zebrafish showed a severe phenotype that could be rescued by mutation of NLPR1 in the same report.

References

  1. 1.0 1.1 "Entrez Gene: DPP9 dipeptidyl-peptidase 9". https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=91039. 
  2. "DPP9 sequesters the C terminus of NLRP1 to repress inflammasome activation". Nature 592 (7856): 778–783. April 2021. doi:10.1038/s41586-021-03350-4. PMID 33731932. 
  3. "Structural and biochemical mechanisms of NLRP1 inhibition by DPP9". Nature 592 (7856): 773–777. April 2021. doi:10.1038/s41586-021-03320-w. PMID 33731929. 
  4. "Dipeptidyl peptidase 9 sets a threshold for CARD8 inflammasome formation by sequestering its active C-terminal fragment". Immunity 54 (7): 1392–1404.e10. July 2021. doi:10.1016/j.immuni.2021.04.024. PMID 34019797. 
  5. "Autoinflammation With Arthritis and Dyskeratosis; AIADK". https://www.omim.org/entry/617388. 
  6. "Human DPP9 represses NLRP1 inflammasome and protects against autoinflammatory diseases via both peptidase activity and FIIND domain binding". The Journal of Biological Chemistry 293 (49): 18864–18878. December 2018. doi:10.1074/jbc.RA118.004350. PMID 30291141. 
  7. Harapas, Cassandra R.; Robinson, Kim S.; Lay, Kenneth; Wong, Jasmine; Moreno Traspas, Ricardo; Nabavizadeh, Nasrin; Rass-Rothschild, Annick; Boisson, Bertrand et al. (September 2022). "DPP9 deficiency: An inflammasomopathy that can be rescued by lowering NLRP1/IL-1 signaling". Science Immunology 7 (75): eabi4611. doi:10.1126/sciimmunol.abi4611. PMID 36112693. 

Further reading